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Abstract
Infection with Mycobacterium ulcerans is characterised by tissue necrosis and immunosuppression due to mycolactone, the
necessary and sufficient virulence factor for Buruli ulcer disease pathology. Many of its effects are known to involve down-
regulation of specific proteins implicated in important cellular processes, such as immune responses and cell adhesion. We
have previously shown mycolactone completely blocks the production of LPS-dependent proinflammatory mediators post-
transcriptionally. Using polysome profiling we now demonstrate conclusively that mycolactone does not prevent translation
of TNF, IL-6 and Cox-2 mRNAs in macrophages. Instead, it inhibits the production of these, along with nearly all other
(induced and constitutive) proteins that transit through the ER. This is due to a blockade of protein translocation and
subsequent degradation of aberrantly located protein. Several lines of evidence support this transformative explanation of
mycolactone function. First, cellular TNF and Cox-2 can be once more detected if the action of the 26S proteasome is
inhibited concurrently. Second, restored protein is found in the cytosol, indicating an inability to translocate. Third, in vitro
translation assays show mycolactone prevents the translocation of TNF and other proteins into the ER. This is specific as the
insertion of tail-anchored proteins into the ER is unaffected showing that the ER remains structurally intact. Fourth,
metabolic labelling reveals a near-complete loss of glycosylated and secreted proteins from treated cells, whereas cytosolic
proteins are unaffected. Notably, the profound lack of glycosylated and secreted protein production is apparent in a range
of different disease-relevant cell types. These studies provide a new mechanism underlying mycolactone’s observed
pathological activities both in vitro and in vivo. Mycolactone-dependent inhibition of protein translocation into the ER not
only explains the deficit of innate cytokines, but also the loss of membrane receptors, adhesion molecules and T-cell
cytokines that drive the aetiology of Buruli ulcer.
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Introduction
Mycolactone is a lipid-like polyketide macrolide virulence factor
produced by Mycobacterium ulcerans, the infectious agent of Buruli
ulcer (BU) [1,2]. This progressive, necrotizing, cutaneous lesion is
common in West Africa but also found in other regions, including
Australia, Asia and South America. Mycolactone is a key factor in
BU pathology: possession of a plasmid carrying enzymes involved
in mycolactone synthesis is essential for virulence and injection of
mycolactone alone can reproduce many characteristics of the
infection, including ulceration, necrosis and suppression of
immune responses [1,3]. Mycolactone has been shown to have
diverse effects on a range of cells and tissues but a unifying
mechanism underlying its pleiotropic actions has remained elusive.
In vitro, exposure to pure mycolactone is cytotoxic for many cell
lines, but the dose and exposure required is highly variable ([4]
and references therein) and primary immune cells (including T-
cells, monocytes and macrophages) are considerably more resistant
[5,6]. While early evidence from cell lines implicated G1/G0
growth arrest and apoptosis [7], recent work showed that a more
likely mechanism driving cell death in vivo is anoikis due to direct
binding of mycolactone to the Wiskott-Aldrich Syndrome Protein
(WASP), leading to inappropriate activation of WASP and
relocalisation of the actin nucleating complex Arp2/3 [8]. This
disrupts the cytoskeleton, altering cell adhesion and migration.
Detachment of monolayer cells is a common feature of the
mycolactone response and precedes cell death by up to 48 hours.
One of the most striking characteristics of BU lesions is an
almost complete absence of inflammation despite extensive tissue
damage. In ulcerated lesions, where large amounts of mycolactone
are produced by foci of extracellular bacilli, inflammatory cell
infiltration is limited to the periphery [9–11]. Infection is
accompanied by alterations in local and systemic immune
responses in which mycolactone plays a central role [11–14], via
direct and indirect effects on T-cells, dendritic cells, monocytes
and macrophages [5,15–17]. Mycolactone interferes with T-cell
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activation, down-regulating expression of the T-cell receptor and
reducing IL-2 production in response to activating signals
[15,17,18]. Lymphocyte homing is also impaired due to suppres-
sion of L-selectin and LFA-1 levels, leading to a dramatic depletion
of T-cells in peripheral lymph nodes [6]. In monocyte-derived
dendritic cells, mycolactone inhibits the production of costimula-
tory molecules (such as CD40 and CD86). In addition, secretion of
various cytokines and chemokines is blocked and mycolactone
treated dendritic cells show a reduced ability to activate T-cells
[16].
The innate immunity provided by monocytes and macrophages
is also suppressed by mycolactone. Tissue resident macrophages
normally play a central role in mycobacterial infections. However,
M. ulcerans differs from other pathogenic mycobacteria in that,
except in very early infection, the vast majority of bacilli are not
found within the host macrophage but are located extracellularly.
Mycolactone inhibits key macrophage responses such as nitric
oxide production and phagocytosis as well as phagosome
maturation and acidification [2,4,19]. In addition, mycolactone
prevents the induction of many proteins essential for driving
inflammation, including TNF, other cytokines/chemokines (for
example, IL-6, IL-8 and IP-10), and further inflammatory
mediators (such as the prostaglandin synthetase Cox-2) [5,10,15].
There is good evidence that mycolactone diffuses through the
lesion in advance of the proliferating bacilli and the necrotic centre
(see for example [20]). Therefore, understanding exactly how this
compound mediates its diverse immunosuppressive and cytotoxic
effects on cells surrounding the developing lesion is crucial. As
outlined above, many of these effects involve loss of expression of
specific proteins, both induced and constitutive, such as inflam-
matory mediators. Consequently, the same molecular mechanism
that prevents inflammatory protein production in the macrophage
may also explain the inadequate protein production more
generally. This makes it an excellent model system with which
to examine the basic cell biology of mycolactone function, since
the response is inducible by nature and it is therefore straightfor-
ward to separate new protein synthesis from baseline levels.
We have previously shown that inducible inflammatory
mediator production is inhibited by a post-transcriptional mech-
anism, since mycolactone does not modulate the LPS-dependent
activation of ERK, JNK, p38 MAPK or NFkB and induced levels
of mRNA are maintained or even enhanced [5]. However there is
no significant decrease in total protein synthesis, nor are
phosphorylation patterns of Akt, p70S6K, eIF4E and eIF2a
changed; a finding confirmed in another model system, Jurkat T-
cells [17]. In the current manuscript we demonstrate conclusively
that mycolactone does not selectively inhibit translation as
predicted [2,5], and instead blocks co-translational translocation
into the ER. This leads to the rapid degradation of mislocalised
proteins in the cytosol and hence loss of detectable expression. We
show that the production of nearly all new glycosylated and
secreted proteins ceases following mycolactone exposure, not only
in macrophages but in fibroblasts, epithelial and endothelial cells.
This mechanism therefore provides the necessary explanation for
many of the pleiotropic effects of this unique molecule and
accounts for much of the underlying disease pathology.
Results
Mycolactone does not inhibit the translation of
proinflammatory mRNAs
In order to establish the dose of synthetic mycolactone A/B
required to completely inhibit the production of TNF in
RAW264.7 cells, we carried out a dose response (Fig. 1A). It
was determined that the effective dose was 125 ng/ml, and this
also prevented LPS-dependent Cox-2 production without affecting
cell viability (Fig. S1A). This dose is marginally higher than
required for inhibition of TNF production by natural mycolactone
A/B in primary human macrophages (Fig. S1B), probably
reflecting the known variation in sensitivity between different cell
types, preparations of mycolactone (natural vs. synthetic) and/or
target activities (immunosuppressive vs. cytotoxic). We then
performed polysome profiling of macrophages to investigate
whether mycolactone selectively inhibits the translation of
inflammatory mediators. This technique allows the association of
TNF, IL-6 and Cox-2 transcripts with actively translating
polysomes in various experimental conditions to be assessed.
RAW264.7 cells were used because, in preliminary experiments,
the low mRNA yields and high RNase content of primary human
monocytes and macrophages precluded the use of these cells (data
not shown). The post-transcriptional mechanism of mycolactone-
dependent inhibition of cytokine production observed in primary
cells is conserved in this cell line (Fig. S1C, performed as a control
experiment for all profiles obtained).
Mycolactone exposure was found to consistently cause a change
in the shape of the polysome profiles, associated with an increase
in the size of the 60S peak and change in the profile in the area
associated with heavy polysomes in both unstimulated (Fig. 1B;
MYC) and stimulated (Fig. 1C; LPS+MYC) cells. However, these
changes occurred gradually over several hours, while the
inhibition of TNF production is manifest as little as 20 min after
LPS addition (data not shown). This suggests it may be a
secondary, rather than primary, effect. Mycolactone alone did not
influence the quantity or location of TNF mRNA (not shown) and
LPS stimulation in itself did not induce any gross changes to the
polysome profiles (Fig. 1C). In each profile, poly-A tract binding
protein (PABP) and b-actin are used as control transcripts that
confirm the location of unformed ribosomes and polysomes,
respectively (Fig. 1C).
While unstimulated RAW264.7 cells expressed very little TNF
mRNA, as expected, LPS stimulation led to increased abundance
Author Summary
Buruli ulcer is a progressive necrotic skin lesion caused by
infection with the human pathogen Mycobacterium ulcer-
ans. Mycolactone, a small compound produced by the
mycobacterium, is the root cause of the disease pathology,
but until now there has been no unifying mechanism
explaining why. We have been using a model system to
investigate the reason for the selective loss of protein that
is a common feature of mycolactone exposure. Specifically,
this involves identifying the point at which it stops
immune cells making inflammatory mediators. In this
work, we demonstrate that mycolactone inhibits produc-
tion of such proteins by blocking the first step of protein
export: translocation into a cellular compartment called
the endoplasmic reticulum (ER). Proteins due for export are
instead made in the cell cytosol where they are recognised
as being in the wrong place and are rapidly degraded,
causing a general cessation of the production of proteins
that have to travel through the ER, including almost all
secreted and surface proteins. This has a profound effect
on basic cell functions such as growth, adhesion and
survival. Therefore, we have identified the molecular basis
underlying the key features of Buruli ulcer, and this will
transform our understanding of disease progression.
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Figure 1. Mycolactone does not change the polysomal association of proinflammatory mRNAs. A. RAW264.7 cells were incubated for
1 hr+/2various concentrations of mycolactone (MYC as indicated), 0.5 mg/ml Actinomycin D (Act D) or 0.0125% DMSO then stimulated or not with
LPS for 4 hr. Supernatant TNF levels were measured by ELISA (mean6SEM of triplicate assays). B–D. RAW264.7 cells were incubated for 1 hr+/2
125 ng/ml mycolactone (MYC) then stimulated or not with LPS. After 4 hrs cells were harvested and lysed in the presence of CHX. B and C. Polysomes
were separated on a 10–50% sucrose gradient and the profiles measured by absorbance at 254 nm. Note the increase in the 60S peak and reduced
height of the polysome peaks in MYC and LPS+MYC samples. RNA was purified from gradient fractions and transcripts were detected by Northern
blotting using full coding region cDNA probes for the genes indicated. D. Signal intensity was quantified by ImageJ analysis of non-saturated
phosphorscreen images. Values are presented as percentage of total signal for control (dashed line), LPS (solid black line) and LPS+MYC (red line)
cells. All are representative of 3 independent experiments. PABP; poly A-tract binding protein.
doi:10.1371/journal.ppat.1004061.g001
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of TNF, IL-6 and Cox-2 mRNAs and their location moved so that
a higher proportion of the mRNAs were in the polysomal fractions
(Fig. 1C, compare ‘control’ and ‘LPS’ - and quantified in Fig. 1D),
due to the known translational derepression that occurs following
stimulation [21]. Again, as expected, neither the location of b-
actin (known to be mycolactone insensitive [5]) or PABP were
affected by mycolactone (Fig. 1B and D). However, in stark
contrast to expectations, mycolactone had no effect on the
polysomal association of any of the three inflammatory transcripts;
all remained in heavy-polysomal fractions (Fig. 1B, compare ‘LPS’
and LPS+MYC’). When quantitated, the distribution of the
mRNAs was very similar in the presence and absence of
mycolactone (Fig. 1D).
We confirmed this unexpected finding in a number of ways.
First, the localisation of these transcripts was assessed at various
times after LPS stimulation to investigate whether the findings
were influenced by the kinetics of the LPS response or time of
mycolactone exposure (.1 hr), but this was found not to be the
case (data not shown). Second, we examined the effects of short
term exposure to two translation-inhibiting drugs on polysome
profiles (Fig. 2A and B). Puromycin (PURO) causes premature
termination and ribosomal release from translating mRNAs,
whereas homoharringtonine (HH) prevents translation initiation
leading to ribosome run-off of translating mRNAs) [22,23].
Neither drug influenced the production of TNF or its inhibition
by mycolactone (Fig. S2), but both caused a change in the profiles
obtained from LPS stimulated cells, with HH being the more
efficient (Fig. 2A). As expected, there was a concomitant change in
the location of b-actin mRNA to monosomes (HH) or lighter
polysomes (PURO) (Fig. 2B, left panel LPS, compare the black
with the blue or green lines respectively). Cox-2 and TNF mRNAs
also both moved into lighter polysomal fractions, confirming that
our experimental system was sensitive to inhibition of translation.
When the action of these drugs on mycolactone treated cells was
assessed, it could be seen that, while mycolactone altered the
profiles but not the location of b-actin, Cox-2 or TNF transcripts
as before (Fig. 2A and 2B, black lines), the response to PURO and
HH was the same in the absence and presence of mycolactone.
For Cox-2, PURO caused a similar ,2-fraction shift (Fig. 2B,
green lines), whereas HH causes a similar ,1-fraction shift
(Fig. 2B, blue lines) in both untreated and mycolactone treated
cells. It is interesting to note that the shift in the Cox-2 peaks
following HH treatments were smaller than that seen for b-actin,
suggesting that Cox-2 is being translated more slowly (compare the
blue lines in Fig. 2B, LPS, Actin and Cox-2). Both drugs had a less
marked effect on TNF but a movement of the peak of mRNA
recovery to lower fractions could be seen that was not prevented
by mycolactone. This shows that all of the tested mRNAs are
undergoing active translation in both the presence and absence of
mycolactone and are not stalled on the ribosomes.
Finally, in an independent approach, the cellular localisation of
proinflammatory mRNAs in the presence of mycolactone was also
examined. Since TNF and IL-6 are secreted proteins and Cox-2, is
ER-resident and contains a signal peptide, their actively-translat-
ing, nascent polypeptide chains should be directly associated with
the ER due to the interaction of the signal peptide with the signal
recognition particle (SRP) and Sec61 complex [24]. Cells were
selectively permeabilised with digitonin to separate the cytosolic
and digitonin-resistant ER membrane fractions. Western blotting
showed the presence GAPDH protein in the cytosol while the ER-
resident protein glucosidase I (GCS1) was confined to the
membrane fraction (Fig. 2C). As seen by others, GAPDH mRNA
was fairly evenly distributed between cytosolic and membrane
fractions [25,26], but the mRNAs for TNF, Cox-2 and IL-6 were
all predominantly in the membrane fraction, even in the presence
of mycolactone, indicating sufficient synthesis had occurred to
allow signal peptide recognition (Fig. 2D). This data also strongly
argues against an inhibition of proinflammatory mRNA transla-
tion as the mechanism underlying the loss of protein production
due to mycolactone.
Inhibition of the 26S proteasome allows the cellular
expression of pro-TNF and Cox-2 in the presence of
mycolactone
As proinflammatory protein synthesis is maintained in the
absence of detectable protein levels, mechanisms by which these
proteins might be targeted for degradation by the cell were
investigated. Degradation by the 26S proteasome seemed a likely
candidate. However, examining this experimentally is complex for
inflammatory mediators since their transcriptional activation
requires proteasome-dependent degradation of IkBa [27]. Cells
were therefore stimulated with LPS for 2 hrs prior to addition of
the proteasome inhibitor (PSI) for an additional 2 hrs. This did not
decrease LPS-dependent production of TNF in cell supernatants
(Fig. 3A) indicating that this experimental design was satisfactory.
Treatment of RAW264.7 cells with mycolactone resulted not
only in a profound decrease in LPS-dependent Cox-2 production,
but the barely detectable immunoreactive protein also had a lower
mol wt (Fig. 3B, compare lanes 2 and 3), equivalent to that seen in
cells exposed to the N-glycosylation inhibitor tunicamycin (TUN;
Fig. 3B lane 4). Remarkably, Cox-2 production was found to
increase when 26S proteasome activity was blocked in mycolac-
tone-treated cells (Fig. 3B, compare lanes 3 [open arrow] and 7
[closed arrow]). When this effect was quantified by densitometry
(Fig. 3C), then considered as fold-change within each experiment,
the extent of restoration of protein production was 2.3160.35-fold
(mean6SEM, P = 0.02, n = 3). Notably, this protein was also
unglycosylated (Fig. 3B, Cox-2 lane 7 [closed arrow]).
An even more striking observation was made for TNF, detected
as nascent pro-TNF (26 kDa) within cell lysates. In LPS-stimulated
cells pro-TNF is rapidly exported and so is barely detectable in cell
extracts (Fig. 3B lane 2). However, while the low-level ER stress
induced by TUN does not reduce TNF in cell supernatants
(Fig. 3A) it does slows transit through the ER and Golgi allowing
detection of pro-TNF in lysates [28] (Fig. 3B, lane 4). In the
absence of PSI, no pro-TNF could be observed following
mycolactone treatment, but levels of pro-TNF increased dramat-
ically upon inhibition of 26S proteasome activity (Fig. 3B,
compare lanes 3 [open arrow] and 7 [closed arrow]). When this
effect was quantified by densitometry and analysed as for Cox-2
(Fig. 3C) this equated to a mean fold-increase of 12.2466.6-fold
(mean6SEM, P = 0.0002, n = 3). This is the first time that the
inhibition of cellular TNF and Cox-2 production has been
overcome in the continuous presence of inhibitory concentrations
of mycolactone, allowing detection of the previously undetectable
protein. This transformative finding supports a mechanism for
mycolactone action in which such proteins (including, but not
restricted to, TNF and Cox-2) are being destroyed by proteosomal
degradation in the cytosol.
Mycolactone inhibits co-translational translocation into
the ER
The lack of glycosylation of Cox-2 and the failure of PSI
treatment to cause TNF secretion (Fig. 3A), suggested the restored
proteins could not gain access to the ER. Indeed, after digitonin
permeabilisation of PSI-treated cells, unglycosylated Cox-2 and
pro-TNF were predominantly found in the cytosolic fraction of
Mycolactone Inhibits Translocation into the ER
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mycolactone treated cells (Fig. 3D, lane 3 [closed arrow]), in
contrast to the LPS-induced proteins that were glycosylated and
membrane associated (Figure 3D lane 6). Unglycosylated Cox-2
was found in the membrane fraction after TUN treatment
showing that lack of N-glycosylation alone was insufficient to
explain its localisation in mycolactone-treated cells (Fig. 3D lane
8). Inhibition of the Sec61 translocon by small molecule inhibitors,
rather than causing accumulation of proteins intended for export
in the cytoplasm, tends to trigger rapid degradation of the
mislocalised proteins [29,30], similarly to mycolactone. We
therefore assessed whether the degradative loss we observe could
be due to a blockade of translocation, using assays in which
different mRNAs (transcribed and capped in vitro) undergo in vitro
translation (IVT) in the absence or presence of ER containing
cellular membrane preparations (Fig. 4). When such membranes
are absent, no modifications of the proteins are possible. However,
when membranes are present, the nascent proteins produced can
undergo co-translational translocation into the ER via the Sec61
Figure 2. Proinflammatory mRNAs are actively translating in the presence of mycolactone. RAW264.7 cells were incubated for 1 hr+/2
125 ng/ml mycolactone (MYC), then stimulated with LPS. A and B. After 4 hr 100 mg/ml puromycin (PURO) or 5 mM homoharringtonine (HH) were
added for 3 min, then CHX was added before lysis and separation of polysomes on a 10–20% sucrose gradient. LPS (solid black line), LPS+PURO (solid
green line) and LPS+HH (dotted blue line). A. RNA profiles measured by absorbance at 254 nm. B. Quantitation of specific mRNAs purified from each
fraction and analysed by Northern blotting. Signal intensity was quantified by ImageJ analysis of non-saturated phosphorscreen images. Values are
presented as percentage of total signal. C and D. Cytosolic and digitonin-resistant membrane fractions were prepared from treated cells as described.
C. Western blot of cell fractions (0.56105 cell equivalents/lane). GCS1; glucosidase I (,92 kDa), GAPDH (,40 kDa). D. total RNA was used as a
template in qRT-PCR absolute quantitation assays and is presented as % total RNA for each gene (mean6SEM). All data representative of 3
independent experiments.
doi:10.1371/journal.ppat.1004061.g002
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translocon and can consequently be either glycosylated or
processed to remove the signal peptide sequence. In agreement
with our other findings, mycolactone had a minimal direct effect
on the synthesis of TNF in both the absence (Fig. 4A; TNF and
luciferase mRNAs) and presence (Fig. 4B, TNF compare lanes 1
and 4) of membranes provided by semi-permeabilised RAW264.7
cell extracts.
In order to test whether TNF could co-translationally translo-
cate into the ER in the presence of mycolactone we used
Proteinase K, which can only digest proteins that it can access (i.e.
those outside of the added membranes). A proportion of newly
synthesised TNF could be protected from Proteinase K digestion,
resulting in a resistant band of slightly lower mol wt (due to loss of
pro-TNF’s cytoplasmic tail, Fig. 4B, lane 2). This protected
fragment was lost on inclusion of detergent (Fig. 4B, lane 3), as
expected, since the Proteinase K could now access proteins in the
internal membrane compartment. Mycolactone efficiently pre-
vented TNF from translocating into the protected membrane
compartment since its addition led to a complete loss of the
Proteinase K resistant band (Fig. 4B, compare lanes 2 and 5). This
inhibition of translocation was dose-dependent (IC50<15 nM,
Fig. 4C).
A complete blockade of TNF translocation into the ER is
necessary and sufficient to explain the loss of TNF production and
rapid degradation we have observed. Co-translational transloca-
tion is a mechanism utilised by many proteins, and there are some
well-established model precursor proteins that can be used to
investigate whether mycolactone’s inhibition is more generally
applicable. The N-glycosylation of yeast prepro-a Factor (PPaF) is
dependent on the addition of canine pancreatic microsomal
membranes (CPMM, Fig. 4D) and can be reversed by the
deglycosylating enzyme Endoglycosidase H (EndoH, Fig. 4E).
Mycolactone reproducibly blocked PPaF from being glycosylated
(Figs 4D and 4E), and this mimicked the activity of another known
translocation inhibitor, Eeyarestatin 1 (ES1, Fig. 4E). Whilst
250 mM ES1 is typically employed to inhibit ER translocation in
vitro [31], much lower levels of mycolactone (0.25–0.7 mM)
achieved a comparable effect (Figs. 4D and 4E; PPaF). The
Figure 3. Mycolactone causes degradation of TNF and Cox-2 by the 26S proteasome in the cytosol. RAW264.7 cells were incubated +/2
125 ng/ml mycolactone (MYC) or 5 mg/ml tunicamycin (TUN) for 1 hr and stimulated with LPS for 4 hrs. In certain samples 5 mM PSI was added 2 hrs
after the LPS stimulation. This allowed time for the proteasome-dependent activation of NFkB required for transcriptional activation to occur before
proteasome activity was inhibited (see text). A. Supernatant TNF levels from cells treated as above, measured by ELISA (mean6SEM). B. Western blot
of cell lysates (0.56106 cell equivalents/lane), the dotted line separates samples with and without PSI treatment for ease of interpretation. C. Signal
intensity was quantified by ImageJ analysis of non-saturated blots and normalised to LPS+TUN (not shown). Values are mean intensity for each
lane6SEM of 3 independent experiments. For Cox-2 this is the unglycosylated mol wt band only (UG Cox-2). *, P,0.05; ***, P,0.001. D. Western blot
of cytosolic and digitonin-resistant membrane fractions from cells treated with PSI as described above. All data representative of (or pooled from, C) 3
independent experiments. G; glycosylated Cox-2 (,80 kDa), UG; unglycosylated Cox-2 (,69 kDa), pro-TNF (,26 kDa), GAPDH (,40 KDa), GCS1;
glucosidase I (,92 KDa). Open arrowheads indicate cells treated with mycolactone but not PSI. Closed arrowheads indicate cells treated with
mycolactone and PSI.
doi:10.1371/journal.ppat.1004061.g003
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precise concentration of mycolactone required for a complete
inhibition of in vitro translocation may be influenced by the amount
of ER derived membranes present in the assay (cf. Figs 4D and
4E). Likewise, the cleavage of the b-lactamase signal peptide can
also be detected after the addition of CPMM, providing an
alternative measure of ER translocation. In this case we observed a
substantial reduction in signal sequence cleavage although the
effect was not complete (Fig. 4D, LACTB).
Mycolactone is a lipid-like molecule that is reportedly present in
the cytoplasm of treated cells [8,32], but an inhibition of
translocation suggests that it may be interacting with the ER
membrane in some way. Cells that are allowed to recover for
24 hr after 1 hr of mycolactone exposure are still unable to
produce TNF, suggesting that this activity is irreversible (Fig. 4F).
To determine whether mycolactone mediates its functions simply
by disrupting organelle membrane structures we studied whether
mycolactone could prevent the insertion of tail-anchored mem-
brane proteins into the ER. Such proteins, including the b subunit
of the Sec61 complex (Sec61b) and cytochrome B5 (Cyt-B5), are
inserted into the ER membrane in a post-translational, Sec61-
independent, manner [33], and are subsequently glycosylated on
artificial C-terminal reporters (Fig. 4E, compare lanes 1 and 2).
While mycolactone prevented the in vitro glycosylation of PPaF,
neither mycolactone nor ES1 affected the N-glycosylation of
Sec61b or Cyt-B5 (Fig. 4E, lanes 3 and 6), ruling out an effect on
either membrane integrity or the N-glycosylation machinery. In
addition, transmission electron microscopy showed that mycolac-
tone did not disrupt the ultrastructure of LPS-stimulated
RAW264.7 (data not shown). On this basis we conclude that the
loss of co-translational translocation into the ER resulting from
treatment with mycolactone reflects a specific blockade of the
membrane translocation machinery.
Mycolactone-dependent inhibition of translocation is not
accompanied by ER-associated degradation (ERAD), ER
stress or WASP activation
While inhibition of translocation across the ER is sufficient to
explain the loss of inflammatory mediators by mycolactone, we
also investigated whether other cellular mechanisms might also
contribute. First, we examined whether it might activate ER-
associated degradation (ERAD) since this pathway can recognise
unfolded proteins, deglycosylate and then degrade them in a
ubiquitin-dependent manner. Specifically we asked whether
Kifunensine (KIF; a class I a-mannosidase inhibitor and a well-
established suppressor of ERAD [34,35]) could overcome
mycolactone-dependent inhibition of protein production reason-
ing that, if this was the case, then KIF treatment should restore
protein production. The biological activity of KIF in this system
was confirmed by monitoring the expression of constitutive Cox-2
expression (Fig. 5A, compare lanes 1 and 4) in the absence of LPS
or mycolactone, since this is known to be turned-over by ERAD
Figure 4. Mycolactone inhibits co-translational translocation of proteins into the ER via a mechanism that does not disrupt the
structural integrity of the ER. A–E. In vitro translation (IVT) reactions of different capped transcripts were performed as described +/2
mycolactone (MYC; 200 ng/ml unless indicated otherwise), Eeyarestatin 1 (ES1; 250 mM) or DMSO (-; 0.02%). Data representative of 3 independent
experiments. A. IVT of luciferase and TNF mRNAs detected by 35S incorporation and Western blot (,26 kDa) respectively. B. IVT of TNF mRNA was
performed in the presence of semi-permeabilised RAW264.7 cells then incubated with no addition (-), or Proteinase K (PK) +/20.1% Triton-x-100 (PKT)
for 1 hr at 4uC before stopping the reaction. C. Dose dependence of loss of the PK protected band. Signal intensity was quantified by ImageJ analysis
of non-saturated blots and the protected band (PK) was normalised to total pro-TNF (-). D. IVT of prepro-a Factor (PPAF) and b-lactamase (LACTB)
mRNAs in the absence or presence of canine pancreatic microsomal membranes (CPMM). Black arrowhead, glycosylated forms of a Factor; *, signal
peptide-cleaved LACTB. E. IVT of PPAF, Sec61b and cytochrome B5 (Cyt-B5) mRNAs in the presence CPMM. After labelling with 35S as described,
membranes were isolated by centrifugation through a sucrose cushion [31]. Endoglycosidase H (EndoH) is used to confirm glycosylation of proteins
(black arrowhead), the thin line represents where an empty lane was removed from the image for ease of interpretation. F. RAW264.7 cells were
incubated +/2125 ng/ml mycolactone (MYC), washed and incubated without mycolactone for various periods (recovery time) before stimulating
with LPS for 4 hrs. Supernatant TNF levels were measured by ELISA (mean6SEM of triplicate assays).
doi:10.1371/journal.ppat.1004061.g004
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[36]. KIF significantly increased Cox-2 expression under these
conditions (Fig. 5B), so we can be sure that it does inhibit ERAD at
this dose in RAW264.7 cells. However, KIF was unable to restore
either production of Cox-2 (Fig. 5A, compare lanes 3 and 6) or
TNF secretion (Fig. 5C) in mycolactone-treated cells. This argues
against mycolactone being an activator of ERAD-dependent ER
export.
In addition, as shown previously in primary human monocytes
[5] and T cells [17], eIF2a was not significantly phosphorylated in
mycolactone-treated RAW264.7 cells (Fig. 5D). Moreover, it did
not cause the phosphorylation of PERK, induce expression of BiP
(Fig. 5D) or cause the IRE-dependent splicing of XBP-1 (Fig. 5E),
in contrast to the known inducer of ER stress, tunicamycin (TUN).
Therefore ER stress, as defined by conventional markers, cannot
explain mycolactone action.
Recently, inappropriate activation of WASP family proteins by
mycolactone was shown to lead to changes in cell adhesion and
migration, some of which are reversed by wiskostatin [8], an
inhibitor of N-WASP GTPase activity. Since actin dynamics might
conceivably contribute to the inhibition of TNF and Cox-2
Figure 5. Mycolactone does not mediate these effects via ERAD, ER stress or WASP-activation-dependent mechanisms. A–C.
RAW264.7 cells were incubated +/2125 ng/ml mycolactone (MYC), +/250 mM Kifunensine (KIF) or 0.0125% DMSO for 1 hr and stimulated or not with
LPS for 4 hrs as indicated. A. Western blot of cell lysates (0.56106 cell equivalents/lane); the thin line represents where an empty lane was removed
from the image for ease of interpretation. B. Quantitation of constitutive expression of Cox-2 in lanes 1 and 4 (control and KIF respectively) Pixel
intensity was determined using ImageJ software and normalised according to GAPDH. Results represent the mean6SEM (n = 3). C. Supernatant TNF
levels measured by ELISA (mean6SEM). D. RAW264.7 cells were incubated +/2125 ng/ml mycolactone (MYC) for various periods or 5 mg/ml
tunicamycin (TUN) or 0.0125% DMSO for 4 hrs. Western blot of cell lysates (0.56106 cell equivalents/lane). E. Total RNA of treated/unstimulated cells
was used as a template for RT-PCR of XBP-1 (upper panel) which was then digested with Pst1 and separated on a 1% agarose gel (lower panel). NTC;
no template control, US; unspliced. F–G. RAW264.7 cells were incubated +/2125 ng/ml mycolactone (MYC), 2/+ wiskostatin at a range of
concentrations or 0.0125% DMSO for 1 hr and stimulated or not with LPS for 4 hrs. F. Supernatant TNF levels measured by ELISA (mean6SEM). G.
Western blot of cell lysates (0.56106 cell equivalents/lane). H. HeLa cells were incubated with a range of doses of mycolactone (MYC) and wiskostatin
or 0.0125% DMSO for 1 hr and stimulated or not with 10 ng/ml IL-1b. IL-6 in supernatants was measured by ELISA (mean6SEM of production,
normalised to IL-6 production in otherwise untreated, IL1b stimulated cells). Cox-2 (,90 kDa), GAPDH (,40 kDa), p-PERK (140 kDa), BiP (,78 kDa),
(p-)eIF2a (,38 kDa).
doi:10.1371/journal.ppat.1004061.g005
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production by mycolactone, as well as cell adhesion, the effect of
wiskostatin in our system was investigated. In contrast to previous
reports in human macrophages [37], wiskostatin itself had an
inhibitory effect on TNFa secretion in RAW264.7 cells (Fig. 5F).
When co-incubated with mycolactone it could not restore protein
production. This included the loss of LPS-induced TNF (Fig. 5F)
and Cox-2 (Fig. 5G) in RAW264.7 cells and the IL1b-induced
production of IL-6 (Fig. 5H) and IL-8 (data not shown) in HeLa
cells at our inhibitory dose of 125 ng/ml. Since the reported
restorative effect of wiskostatin on HeLa cell adhesion was
determined using a lower dose of natural mycolactone A/B [8]
we examined wiskostatin’s effect at a range of doses of both
mycolactone and wiskostatin, but could find no evidence to
support an influence of WASP inhibition over cytokine production
(Fig. 5H).
Mycolactone prevents the production of the vast
majority of N-glycosylated and secreted proteins that
transit through the ER
Translocation of proteins into the ER is a widespread cellular
phenomenon but is nevertheless restricted to a defined subset of
proteins, most of which carry a canonical signal peptide. Our
findings suggest that in mycolactone-exposed cells, the production
of most proteins within this subset may be blocked. We tested this
by examining protein synthesis in different cellular compartments
(Fig. 6A and B). The translation elongation inhibitor cyclohexi-
mide (CHX) led to an almost complete block in protein synthesis
in both cytosolic and membrane fractions of RAW264.7 cells, as
expected. Yet, while mycolactone caused little change in cytosolic
protein synthesis, it did cause a selective ,30% decrease in
membrane-associated proteins (Fig. 6A and B, P,0.01). Since the
membrane fraction would include proteins from various intracel-
lular organelles (nucleus, mitochondria etc) as well as exported
proteins, Concanavalin A (ConA) agarose was used to isolate
glycosylated proteins in order to better represent the subset of
proteins that must translocate into the ER. As predicted, a large
decrease in the recovery of such constitutive and induced proteins
from mycolactone-treated cells was found (Fig. 6C). Notably, the
degree of loss varied and a minority of proteins showed little or no
change. When supernatants were examined, the abundance of
almost all constitutive and LPS-induced proteins was reduced,
with only a single ,32 kDa protein unaffected (Fig. 6C). This was
dose-dependent (Fig. 6D) and production of most mycolactone-
sensitive proteins showed similar IC50 values (57.867.9 nM,
mean6SEM, n = 3). Indeed, when we investigated the production
of 18 cytokines and chemokines produced by RAW264.7 cells (Fig.
S3A), we found that 17 were almost completely blocked by
mycolactone after LPS stimulation (Fig. S3B and C). Those not
reported as targets of mycolactone previously include TIMP-I,
soluble ICAM-1 and IL-RA. A single chemokine, MIP-1a seemed
to be completely insensitive to mycolactone inhibition in this
antibody array, however validation by ELISA showed that these
antibodies may be saturated by the high levels of constitutive
protein, since this more quantitative analysis showed a profound
inhibition by mycolactone (Fig. S6D). A similar phenomenon is
most likely also responsible for the apparent reduced sensitivity of
constitutively expressed JE (CCL2, commonly known as MCP-1 in
humans) and MIP-1b in the absence of LPS (Fig. S3B and C),
especially since others have previously shown that both are
mycolactone targets in other systems [16,18].
Since many different types of cells are exposed to mycolactone
in BU lesions and translocation by the Sec61 complex is highly
conserved [38], we examined whether the production of
secreted and glycosylated proteins would be similarly prevented
in non-immune cells. Interestingly this was found to be the case in
human dermal microvascular endothelial cells (HDMVEC),
murine L929 fibroblasts and HeLa cells (Fig. 6E). In all cases,
there was a profound inhibition of protein production affecting the
majority of proteins in these compartments. Therefore, a block in
translocation of proteins into the ER represents a widely
applicable mechanism underlying mycolactone’s pathogenic
effects.
Discussion
In this manuscript we have identified an important new activity
for the M. ulcerans virulence factor, mycolactone. By investigating
the inhibition of cytokine production as a model system to
examine its basic cell biology, we have shown that mycolactone
effectively blockades the translocation of nascent proteins across
the ER membrane in a mechanism that seems to involve the Sec61
translocon. This finding is remarkable because previous data
suggested that mycolactone was probably inhibiting the translation
of inflammatory mediators such as TNF, IL-6 and Cox-2 [2,5].
However, our detailed investigation refutes this. We showed
conclusively that the transcripts were actively translating in vitro
and in a RAW264.7 cell model in both the absence and presence
of mycolactone. The polysomal location of each of these
transcripts in treated cells is remarkably similar to that seen in
untreated cells and their relocation in response to inhibitors of
translation is also unaffected. Likewise the demonstration of an
association between these mRNAs and the membrane fraction in
mycolactone-treated cells provides independent evidence of
sufficient translation having occurred to allow signal peptide-
directed targeting to the ER.
We provide multiple lines of evidence in support of mycolac-
tone’s ability to prevent translocation across the ER and induce
subsequent degradation in the cytosol. This is supported first by
the finding that translocation of TNF into a protease resistant
membrane compartment could no longer occur in the presence of
mycolactone in vitro. Furthermore, production of both Cox-2 and
cellular pro-TNF was restored when the protease activity of the
proteasome was blocked by PSI after transcriptional activation and
translational derepression had occurred. The restored Cox-2 was
unglycosylated; however this is most likely a consequence of never
having entered the ER rather than a cause of degradation. The
effects of TUN and mycolactone on TNF secretion and Cox-2
production are quite distinct and the restored Cox-2 and TNF
were both present in the cytosol rather than the membrane.
Therefore, while blocking the proteasome prevented the degra-
dation of the proteins, it could not overcome mycolactone’s
translocation blockade and the restored proteins would not be able
to carry out their normal cellular function. Proteasome inhibitors
such as Bortezomib have attracted some attention as cancer
therapeutics, but for the reasons laid out above such drugs should
not be considered for BU treatment.
There are a number of mechanisms by which proteins can enter
the ER and then go on to be secreted, retained in the ER or
inserted into the membrane. These include co- and post-
translational Sec61-dependent translocation as well as Get/
TRC40-dependent insertion of tail anchored proteins, reviewed
in [39]. Among cytokines, TNF is slightly unusual in that it is
made as pro-TNF, co-translationally inserted into the ER
membrane as a Type II membrane protein then cleaved at the
cell surface (by TNF-converting enzyme; TACE). Most others,
including IL-6, undergo conventional trafficking via post-transla-
tional translocation into the ER, followed by signal sequence
cleavage. IL-1b and IL-18 provide notable exceptions to this rule,
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Figure 6. Mycolactone specifically targets membrane and secreted proteins. Cells in Met/Cys free medium were incubated +/2125 ng/ml
mycolactone (MYC), 10 mg/ml cycloheximide (CHX) or 0.0125% DMSO for 1 hr and stimulated with LPS for 1 hr before replacement with fresh
medium containing Tran35slabel for 2 hrs. Data representative of 3 independent experiments (A–D). A. Cytosolic and digitonin-resistant membrane
fractions from treated RAW264.7 cells (105 cell equivalents/lane). B. Quantification of 35S incorporation in (A) by scintillation counting (mean6SEM,
n = 3). *, P,0.05; **, P,0.01; ***, P,0.001. C. Total cell lysates, Concanavalin A (ConA) agarose precipitated proteins (Glycosylated) and supernatants
(Media) from RAW264.7 cells. D. Dose dependence of the suppression of supernatant protein production in RAW264.7 cells. E. ConA precipitated
(Glycos) and supernatant proteins (Media) from 35S labelled Human microvascular dermal epithelial cells (HDMVEC), L929 fibroblasts and Hela cells. In
each case total cell labelling was comparable between samples (not shown).
doi:10.1371/journal.ppat.1004061.g006
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and are secreted by an unconventional mechanism following
cleavage of the cytosolic pro-isoforms in a caspase- and
inflammasome-dependent manner [40]. The precise cellular
mechanism that results in consequent export of mature cytokines
is still somewhat controversial. Neither IL-1b nor IL-18 can be
made by RAW264.7 cells (see Fig. S3C) as they lack the required
ASC (Apoptotic speck protein containing a caspase recruitment
domain [41]), and so they were not studied further here. However,
it is interesting to note that in our previous work with primary
human monocytes, IL-1b production was only partially blocked by
mycolactone (between 30–70% depending on the TLR ligand
used to activate the cells [5]). The ability of mycolactone to inhibit
unconventional secretion is now the subject of further investiga-
tion.
To our knowledge, mycolactone is the first and only virulence
factor shown to inhibit translocation into the ER. A very few, non-
pathogenic, compounds have been described that block Sec61-
mediated transport: the substrate selective inhibitors cotransin
(derived from the natural product HUN-7293) and its close
relative CAM741, as well as ES1 and Apratoxin A. In each case a
block in the cotranslational translocation of exported peptides
leads to their rapid degradation in the cytosol [29–31,42]. ES1 is
arguably the best characterised of the translocation inhibitors but
it must be used at a much higher dose (8 mM for treatment of cells,
250 mM in IVT) than is required for mycolactone-dependent
inhibition. In a direct comparison, both were found to be similarly
inactive against the insertion of tail-anchored proteins (Fig. 4E). In
addition to its ability to inhibit entry into the ER, ES1 also inhibits
ERAD driven exit and triggers an unfolded protein response
([43,44] and data not shown). We investigated both these other
pathways here. The inability of KIF to enhance expression of TNF
or Cox-2 in the presence of mycolactone makes increased export
of misfolded proteins via the ERAD pathway an unlikely
mechanism contributing to the loss of inflammatory mediators
(Fig. 5A and B). Moreover, we found no evidence of induction of
the unfolded protein response in mycolactone-treated cells.
Therefore mycolactone’s cellular effects are similar to, but discrete
from, ES1.
In contrast to mycolactone and ES1’s ability to prevent the
production of nearly all glycosylated and secreted proteins
(Fig. 6C–E and [31]), cotransin is both non-toxic and highly
selective in its action, affecting only a small subset of substrates
[30]. Apratoxin A causes a wide inhibition of protein secretion but,
also differs from mycolactone because its effects are completely
reversible [42]. To date in the literature, there have been
contradictory reports on the reversibility of mycolactone action.
While L929 fibroblasts are reported to regrow after the removal of
mycolactone [1], dendritic cells cannot regain the ability to
respond to maturation stimuli after a prolonged exposure (24 hrs)
[16]. Here we show that, for cytokine production, the effects
remain irreversible after 24 hours, even after a brief exposure
(Fig. 4F).
The recently reported ability of mycolactone to enhance actin
polymerisation and inappropriately activate WASP [8] does not
seem to be a major contributor to the inhibition of production of
inflammatory mediators. Mutations in human WASP are associ-
ated with a range of immune dysfunction disorders and WASP has
also been implicated in Golgi to ER transport [45,46]. However,
doses of the WASP inhibitor wiskostatin (equivalent or higher than
those shown to partially restore adhesion in HeLa cells [8]) could
not restore secreted protein production at a range of doses of
mycolactone (Fig. 5F–H). Therefore, the decisive step in
mycolactone-dependent inhibition of protein production seems
to depend on the translocation blockade rather than WASP
activation. Determining the precise mechanism by which myco-
lactone blocks translocation into the ER, and the molecular
consequences of this action are the subject of ongoing investiga-
tion. It will be interesting to determine the molecular explanation
of how some signal-peptide containing proteins including b-
lactamase (Fig. 4D) and CCR7 [17] escape this translocation
block. Indeed selectivity in mycolactone action has been fairly
widely reported and the variable sensitivity to mycolactone
inhibition observed in our in vitro translocation assays is consistent
with this [5,6,16–18].
The broad spectrum inhibition of protein translocation induced
by mycolactone in various cell types has important implications
across diverse pathologies of Buruli ulcer. The suppression of
innate and adaptive immune responses mediated by secreted
cytokines and chemokines is one important aspect of this. In this
work, we have identified nine novel immune proteins that are
sensitive to mycolactone (BCA, MIP-2, G-CSF, GM-CSF, IL-27,
C5/C5a, sICAM-1, IL-1RA and TIMP-1). In addition, the
general block in production of glycosylated proteins would also
affect many other proteins destined for the cell surface that
mediate essential cellular functions. This would include those
involved in aspects of adaptive immunity driven by maturation
markers and costimulatory molecules on dendritic cells [16] where
an inability to produce these proteins would lead to a failure to
interact with lymphocytes, causing the T cell anergy seen in BU
[2,47,48]. Likewise, the loss in T cell homing has been attributed
to loss of receptor expression and this powerful mechanism of
suppression would substantially add to the effect of let-7b [6].
These authors did investigate the role of proteasomal inhibition
with MG132, but the experimental technique used (flow cytometry
of fixed, permeabilised cells) would probably be insensitive to the
restoration of protein that would now be located in the cytosol (see
Fig. 3D) and therefore unlikely to be in its native conformation. In
addition, the translocation block may contribute, along with
WASP activation [8], to the rounding up and loss of adhesion seen
in fibroblasts due to gradual loss of cell adhesion molecules as they
turn over. Since anoikis is described as driving cell death, this
could be an important contributory factor in the necrosis seen in
ulcers. Moreover, a steady depletion of endogenous proteins in this
way would lead to a gradual winding down of cellular function,
rather than rapid cell death, which ties in well with the slow
progression of the disease in humans, as well as in vitro and in vivo
data [4]. For instance, the delay between injection of even 100 mg
of mycolactone into guinea pig and ulcer formation is 5 days [1],
although some early signs of apoptosis are evident from 2 days [7].
BU is the third most common human mycobacterial infection in
the world after tuberculosis and leprosy. Although not fatal,
patients can suffer lifelong disfigurement and disability unless the
infection is recognised and treated at an early stage. Treatment
with antibiotics is often accompanied by increased swelling and
ulceration, or even the appearance of new lesions [49]. Such
paradoxical responses are thought to arise from a gradual increase
in proinflammatory activity as mycolactone levels decline. Several
studies in both human patients and animal models have shown
that a progressive and structured immune response follows
initiation of therapy with the standard rifampicin/streptomycin
combination [20,50,51]. As bactericidal activity does not always
correlate with healing rate, it has been suggested that the drugs,
rifampicin in particular, may inhibit the ability of M. ulcerans to
synthesise mycolactone and that this is the more important factor
in recovery [51,52]. It seems unlikely that this phenomenon is due
to a direct effect of the antibiotics on the immune system.
Although rifampicin is reported to be immunomodulatory,
responses vary and while some proinflammatory responses are
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enhanced by exposure to the drug, others are blocked [53,54]. The
molecular mechanisms of these effects seem independent from
Sec61-dependent translocation and are mostly upstream of this
process. In Jurkat T cells for example, rifampicin inhibits TNF
production by blocking NFkB activation [54]. However, the
possibility that antibiotics may promote restoration of immune
function by altering the interaction between mycolactone and its
cellular target cannot yet be ruled out and is worth investigating. A
greater understanding of these interactions would give insights
valuable to improving diagnosis and treatment of this debilitating
disease. Furthermore, unravelling the mechanisms of mycolactone
activity should also yield novel insights into the vital, basic cellular
process of ER translocation.
Materials and Methods
Reagents
A full list of reagents, primers and antibodies can be found in
Information S1. We used synthetic mycolactone A/B (kind gift of
Prof. Yoshito Kishi, Harvard University) throughout these
investigations [55]. All reagents used in tissue culture were
routinely tested for endotoxin contamination by LAL assay
(Lonza) and were ,0.1 U/ml LPS.
Cell culture and stimulation
The RAW264.7 murine macrophage cell line (ATCC) was
routinely cultured at 37uC and 5% CO2 in high glucose DMEM
medium (PAA) supplemented with 10% FBS (Life Technologies).
Culture conditions for additional cell types can be found in
Information S1. Cells were pre-incubated with mycolactone or
other inhibitors for 1 hr before stimulation with 100 ng/ml TLR-
grade LPS (Enzo Life Sciences) then incubated for 1–4 hr before
harvesting of cells and culture supernatants. Mycolactone was
routinely used at a final concentration of 125 ng/ml; DMSO
diluted to the same extent (0.0125%) was the control. Other
inhibitors used were PSI (5 mM, Calbiochem), CHX (10 mg/ml),
ActD (2 mg/ml), KIF (50 mM), TUN (5 mg/ml), and wiskostatin
(1 mM). For proteasome dependent degradation experiments, cells
were pre-incubated with mycolactone or TUN and stimulated
with LPS for 2 hr, prior to the addition of PSI for a further 2 hr.
To investigate the reversibility of mycolactone action, cells were
exposed to mycolactone for 1 hr, then mycolactone was removed,
the cells were washed with PBS then incubated in complete
DMEM for the indicated time, after which cells were stimulated
with LPS for 4 hrs before harvesting the supernatants. HeLa cells
were stimulated with 10 ng/ml recombinant IL-1b (Peprotech).
Polysome profiling
Polysome profiling by sucrose density gradient ultracentrifuga-
tion was carried out according to a previously published method
[56,57]. A full protocol can be found in Information S1. Briefly,
treated RAW264.7 cells were harvested 10 min after ribosomes
were stalled with CHX (10 mg/ml). In some cases, 100 mg/ml
PURO or 5 mM HH were added 3 min prior to addition of CHX.
Cell lysates were separated over a 10–50% sucrose gradient. RNA
was extracted from 1 ml fractions and analysed by Northern
blotting using 32P-labelled (full coding region) cDNA probes.
Digitonin permeabilisation
Membrane bound and cytosolic cellular fractions were separat-
ed by digitonin permeabilisation using a previously published
method [26] with minor alterations (full protocol in Information
S1). Briefly, proteins from treated RAW264.7 cells were extracted
by sequential use of permeabilisation (0.03% digitonin) and
solubilisation (1% NP-40, 0.5% sodium deoxycholate) buffers.
In vitro translation
TNFa cDNA was prepared from LPS-stimulated primary
human monocytes by RT-PCR and capped mRNA synthesised
using Message Machine (Applied Biosystems). Control mRNAs
(luciferase, a Factor and b lactamase) were all from Promega. In
vitro translation (IVT) reactions were carried out using nuclease-
free rabbit reticulocyte lysates (Promega) with 0.5–1.0 mg mRNA.
Mycolactone was diluted in 5% (w/v) BSA in nuclease-free water
before addition, controls contained BSA alone. Where used, canine
microsomal membrane (CPMM) preparations (Promega, or
prepared in house [58]; a kind gift of Prof Barnhard Dobberstein
[University of Heidelberg]) or semi-permeabilised RAW264.7 cell
extracts freshly prepared as described in [59] were added to a final
concentration of 10%. Samples were incubated for 30 min at 30uC.
For protease protection assays, samples were diluted in 1:5 in
20 mM TrisCl pH 8.0, 10 mM CaCl2 and split into 3 aliquots: to
the control sample buffer alone was added to a final volume of 50 ml,
the second aliquot contained 20 mg/ml Proteinase K and the third
20 mg/ml Proteinase K and 0.1%Triton-x-100. Samples were
incubated for 1 hr at 4uC, then reactions were stopped by addition
of 5 mM PMSF and boiling sample load buffer. For glycosylation
assays of tail-anchored proteins and PPaF, ES1 was pre-incubated
with in-house CPMM for one hour before the addition to other
components. Mycolactone-containing CPMM were used immedi-
ately. Membranes were recovered as described [31] by centrifuga-
tion through 750 mM sucrose, 500 mM KOAc, 5 mM Mg(OAc)2,
50 mM HEPES-KOH (pH 7.9) at 100,0006g for 10 mins. The
membrane pellet was resuspended in 100 mM sucrose, 100 mM
KOAc, 5 mM Mg(OAc)2, 50 mM HEPES-KOH (pH 7.9), 1 mM
DTT and treated with 250 mg/ml RNaseA at 37uC for 10 mins to
remove any residual peptidyl-tRNA species. Samples were separat-
ed by SDS-PAGE. Luciferase, a Factor, b lactamase, Sec61b and
Cyt-B5 were detected by labelling with 35S methionine; TNFa was
detected by SDS-PAGE (15% acrylamide) and Western blotting.
DNA amplification
Total RNA was extracted from cell lysates or digitonin
permeabilised fractions using the RNeasy kit (Qiagen) and
quantified by Nanodrop. One-step qRT-PCR gene expression
assays (Life Technologies) were carried out on either an Applied
Biosystems 7900 (Life Technologies) or on a Stratagene Mx3005P
(Stratagene). For relative gene expression the DDCt method was
used. For absolute quantitation, full-length murine cDNAs were
prepared and used to form standard curves. XBP-1 splicing was
investigated by RT-PCR of total RNA followed by Pst1 digestion
as described [60].
Immunochemistry
Secreted TNF was detected in culture supernatants by ELISA.
For Western blots, cells were lysed directly in gel sample buffer
then sonicated or permeabilised with digitonin. Proteins were
separated by SDS-PAGE (12.5% acrylamide) followed by
conventional blotting. Where quantitation was performed, pixel
density was assessed using ImageJ analysis of non-saturated images
and data were normalized to an appropriate loading control
(GAPDH)
Metabolic labelling
Metabolic labelling was performed as previously described [5].
Met/Cys-starved cells were stimulated as described above for
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2 hrs before the addition of 0.37MBq Tran35S-Label for a further
2 hr at 37uC. They were then either lysed in 20 mM TrisCl,
pH 7.4, 0.5M NaCl, 1% Triton-X-100. 16 protease inhibitor
cocktail) or separated into cytosolic and membrane fractions as
described above. Samples were separated by SDS-PAGE, exposed
to a phosphorimager screen and analysed using a Personal FX
imager (BioRad).
Accession numbers
a factor (PPaF), b-actin: P60710, BiP: P20029, Cox-2: Q05769,
Cytochrome b5: P00167, EIF2a: Q6ZWX6, GAPDH: P16858,
Glucosidase 1: Q80UM7, IL6: P08505, b lactamase: Q9L5C7,
Luciferase: P08659,: P01149, PABP1: P29341, PERK: Q9Z2B5,
TNF (murine): P06804, TNF (human): P01375, Sec61b: P60468,
XBP1: Q6ZWX6.
Supporting Information
Figure S1 Synthetic mycolactone prevents production of
proinflammatory proteins in RAW264.7 cells by a post-
transcriptional mechanism and is not cytotoxic under
the conditions used. A. RAW264.7 cells were incubated for
1 hr +/2 various concentrations of mycolactone (as indicated),
0.5 mg/ml Actinomycin D (Act D) or 0.0125% DMSO then
stimulated or not with LPS for 4 hr. A. Cell viability as assessed by
MTT assay, expressed as a percentage of control cells (mean6-
SEM, n = 3). B. Primary human monocyte-derived macrophages
or RAW264.7 cells were treated for 1 hr with natural mycolactone
A/B (MYC), 2 mg/ml ActD, 10 mg/ml cycloheximide (CHX) or
0.001% EtOH then stimulated with LPS for 2 hrs. TNF in
supernatants was quantified by ELISA and normalised to
production without inhibitors; Mean6SEM of 4 independent
experiments (separate donors for primary cells). C. RAW264.7
cells were incubated +/2125 ng/ml mycolactone for 1 hr then
stimulated with LPS for 4 hr before harvesting for polysome
profiling. Left panel: Supernatant TNF levels at time of harvest as
determined by ELISA. Right panel: total RNA from a portion of
cell lysate was used as a template for qRT-PCR relative gene
expression assays for TNF mRNA.
(TIF)
Figure S2 TNF secretion is not affected by short term
exposure to puromycin and homoharringtonine. A.
RAW264.7 cells were incubated +/2125 ng/ml mycolactone
for 1 hr then stimulated with LPS for 4 hr then incubated with
puromycin (PURO) or homoharringtonine (HH) for 3 mins as
described in the legend of Fig. 2. Immediately before lysing,
supernatants were harvested and assayed for TNF by ELISA
(Mean6SEM of triplicate values as percentage of control).
(TIF)
Figure S3 Mycolactone inhibits the secretion of most
cytokines, chemokines and other inflammatory media-
tors. RAW264.7 cells were incubated for 1 hr +/2125 ng/ml
mycolactone then stimulated or not with LPS overnight (16 hrs)
and supernatants were used undiluted to probe the Mouse
Cytokine Array, Panel A. A. Cytokines detected by the array
(R&D systems (http://www.rndsystems.com/
product_detail_objectname_mousecytokinearraypanela.aspx).
The orange and yellow highlights indicate proteins that were
detected with either high (normalised intensity .1.0) and low
(normalised intensity ,1.0) abundance, respectively B. Pixel
intensity was determined using ImageJ software and normalised
according to the positive control signals. Values represent the
mean of duplicate spots 6 range. The asterisk (*) represents
proteins that are produced constitutively by RAW264.7 cells C.
Raw data for the arrays; reference spots (used to orient the array
and to normalise between arrays) are boxed. Proteins produced by
LPS stimulated cells are indicated for reference only; orange;
strong intensity, yellow, weaker intensity. Note that expression is
relative between treatments and differences in intensity between
proteins are not necessarily quantitative. D. RAW264.7 cells were
incubated +/2125 ng/ml mycolactone for 1 hr then stimulated
with LPS for overnight. TNF and MIP-1a levels were measured by
ELISA.
(TIF)
Information S1 Extended experimental procedures.
Contains a full list of reagents, primers and antibodies as well as
detailed protocols including those for polysome preparation,
digitonin permeabilisation and ConA precipitation.
(PDF)
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